Mp49-12 penile and Uterine Cervical Squamous Cell Carcinomas: A Comparative Genomic Profiling Study

Abstract

who are fit for treatment. We present the experiences of our two supraregional penile cancer referral centres.METHODS: We conducted a retrospective audit of pN3 patients with SCCp at our two centres. Inclusion criteria was any patient whose disease was deemed suitable for adjuvant therapy by the supra-network MDT. Patients who did not start or complete treatment were included in an intention to treat analysis. We recorded dose, site and timing of delivery of radiotherapy AE chemo -sensitisation. Site and timings of recurrence post treatment were established, and both disease specific and overall survival calculated from the date of last lymph node dissection.RESULTS: A total of 151 patients were included. 124 completed radiotherapy AE chemo sensitisation. 23 did not receive treatment and treatment was stopped in 4 cases. Median age was 59 years (range 32-94). Adjuvant (chemo)radiotherapy was administered at a median 75.5 days (range 12 -249) after final nodal surgery. Most commonly used dosing regimen was 45Gy in 20 fractions. Cisplatin was the most commonly used chemo sensitization agent, used in 24% ( 27), 47% ( 53) had no chemotherapy.The mean time to relapse was 8.5 months for the whole cohort, (median 5.5 months). Disease free survival at 5 years was 47.1%. Of the 124 who completed adjuvant treatment 54 relapsed. 50% ( 27) were in field relapses (inguinal or pelvic). In comparison 17 of the 27 who did not have treatment progressed with evidence of inguinal or pelvic involvement in 76.4% (13) of patients after lymphadenectomy.The 5 year cancer specific survival for the whole cohort and adjuvant treatment groups were 44.5% and 47% respectively compared to 31% who did not receive or complete treatment.CONCLUSIONS: Our survival data compares favourably to published data on pN3 survival. This suggests that adjuvant chemoradiotherapy has a role in managing patients with pN3 disease which is associated with a poorer prognosis than pN1 or pN2 patients. The InPACT trial; NCT02305654 is testing the role of chemotherapy vs chemoradiotherapy vs upfront surgery in a randomised control trial.